2024
Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy
Ma J, Dong C, Qiao H, Barret O, Tamagnan G, Mao W, Xu E, Zhang C, Lu J, Chan P, Liu S. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy. Movement Disorders 2024, 39: 847-854. PMID: 38477228, DOI: 10.1002/mds.29769.Peer-Reviewed Original ResearchVesicular monoamine transporter 2Vesicular monoamine transporter 2 bindingProgressive supranuclear palsy groupPositron emission tomographyProgressive supranuclear palsyHealthy controlsParkinson's diseaseStriatal VMAT2 bindingMonoamine transporter 2Mini-Mental State ExaminationNucleus accumbensMontreal Cognitive AssessmentVMAT2 bindingRating ScaleCognitive AssessmentSubstantia nigraMini-MentalSupranuclear palsyState ExaminationProgressive Supranuclear Palsy Rating ScaleHippocampusPET/computed tomographyPD groupClinical characteristicsStriatum
2023
18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease
Huang A, Liu S, Barret O, Qiao H, Tamagnan G, Liu X, Fan C, Li Z, Lu J, Chan P, Xu E. 18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease. Parkinsonism & Related Disorders 2023, 120: 105979. PMID: 38241952, DOI: 10.1016/j.parkreldis.2023.105979.Peer-Reviewed Original ResearchPostural instability gait difficultyMotor subtypesParkinson's diseaseStandardized uptake value ratioDifferent motor subtypesStriatal dopaminergic depletionParkinsonian motor symptomsUptake value ratioPET/CTDopaminergic disruptionMonoaminergic depletionMonoaminergic changesDopaminergic depletionMotor symptomsPIGD scoresDorsal putamenPD subtypesVentral putamenPD pathogenesisPrognosis evaluationPatientsDominant subtypeMethods SixtyAccurate diagnosisDifferent subtypes
2018
IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY
Stephens A, Seibyl J, Mueller A, Barret O, Berndt M, Madonia J, Kroth H, Bullich S, Pfeifer A, Muhs A, Tamagnan G, Marek K, Dinkelborg L. IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. Alzheimer's & Dementia 2018, 14: p179-p179. DOI: 10.1016/j.jalz.2018.06.2287.Peer-Reviewed Original ResearchP1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION
Tempest P, Ono M, Higuchi M, Shimada H, Suhara T, Zhang M, Tai C, Carroll V, Tamagnan G, Marek K, Barret O, Alagille D, Jang M. P1‐400: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. Alzheimer's & Dementia 2018, 14: p455-p455. DOI: 10.1016/j.jalz.2018.06.408.Peer-Reviewed Original ResearchIC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION
Tempest P, Ono M, Higuchi M, Shimada H, Suhara T, Tai C, Tamagnan G, Carroll V, Alagille D, Barret O, Marek K, Jang M. IC‐P‐082: TAU AND ALPHA‐SYNUCLEIN SELECTIVE BINDING COMPOUNDS DERIVED FROM APRINOIA THERAPEUTIC'S PM‐PBB3 BINDING‐SITE FOCUSED COMPOUND COLLECTION. Alzheimer's & Dementia 2018, 14: p71-p71. DOI: 10.1016/j.jalz.2018.06.2146.Peer-Reviewed Original ResearchEvaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals (P5.263)
Koike T, Miyamoto M, Nishi T, Sunahara E, Hasegawa S, Watanabe S, Ikeda S, Ishii T, Kondo S, Takahashi J, Hirabayashi H, Alagille D, Barret O, Tamagnan G, Kuroita T. Evaluation of pharmacodynamic effects of cholesterol 24-hydroxylase inhibitor TAK-935 and its target engagement in animals (P5.263). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p5.263.Peer-Reviewed Original ResearchT156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN
Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, McCarthy T, Zhang L, Gray D, Villalobos A, Lee C, Chen J, Seibyl J, Marek K. T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN. Schizophrenia Bulletin 2018, 44: s176-s176. PMCID: PMC5888516, DOI: 10.1093/schbul/sby016.432.Peer-Reviewed Original ResearchLogan graphical analysisNon-human primatesRhesus monkeysD1 receptorsBlockade studiesPET studiesPET radiotracersD1 receptor occupancyWhole-brain uptakeNovel PET radiotracersInhibitory G proteinSame dose levelMin post injectionHealthy human volunteersTest-retest reproducibilityBrain PET studiesPET imaging tracerAgonist PET tracerClinical studiesStriatal regionsInjected dosePsychiatric disordersCerebellar cortexDose levelsReceptor occupancy
2017
[IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES
Mueller A, Kroth H, Schieferstein H, Berndt M, Oden F, Capotosti F, Molette J, Juergens T, Darmency V, Schmitt‐Willich H, Hickman D, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. Alzheimer's & Dementia 2017, 13: p141-p142. DOI: 10.1016/j.jalz.2017.06.2567.Peer-Reviewed Original Research[IC‐P‐198]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3
Shimada H, Kitamura S, Ono M, Kimura Y, Ichise M, Takahata K, Moriguchi S, Kubota M, Ishii T, Takado Y, Seki C, Hirano S, Shinotoh H, Sahara N, Tempest P, Tamagnan G, Seibyl J, Barret O, Alagille D, Zhang M, Kuwabara S, Jang M, Marek K, Suhara T, Higuchi M. [IC‐P‐198]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3. Alzheimer's & Dementia 2017, 13: p146-p146. DOI: 10.1016/j.jalz.2017.06.2573.Peer-Reviewed Original Research[P3–378]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3
Shimada H, Kitamura S, Maiko O, Kimura Y, Ichise M, Takahata K, Moriguchi S, Kubota M, Ishii T, Takado Y, Seki C, Hirano S, Shinotoh H, Sahara N, Tempest P, Tamagnan G, Seibyl J, Barret O, Alagille D, Zhang M, Kuwabara S, Jang M, Marek K, Suhara T, Higuchi M. [P3–378]: FIRST‐IN‐HUMAN PET STUDY WITH 18F‐AM‐PBB3 AND 18F‐PM‐PBB3. Alzheimer's & Dementia 2017, 13: p1104-p1104. DOI: 10.1016/j.jalz.2017.06.1594.Peer-Reviewed Original Research[P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES
Mueller A, Kroth H, Schieferstein H, Berndt M, Oden F, Capotosti F, Molette J, Juergens T, Darmency V, Schmitt‐Willich H, Hickman D, Tamagnan G, Pfeifer A, Dinkelborg L, Muhs A, Stephens A. [P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. Alzheimer's & Dementia 2017, 13: p774-p774. DOI: 10.1016/j.jalz.2017.06.1036.Peer-Reviewed Original Research[IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS
Barret O, Seibyl J, Stephens A, Madonia J, Alagille D, Mueller A, Berndt M, Kroth H, Capotosti F, Muhs A, Pfeifer A, Tamagnan G, Dinkelborg L, Marek K. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. Alzheimer's & Dementia 2017, 13: p3-p4. DOI: 10.1016/j.jalz.2017.06.2625.Peer-Reviewed Original ResearchEffect of Leaving Group Substituents on the Microfluidic Synthesis of [18F]3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]FPEB)
W. Kabalka G, M. Moore T, R. Akula M, Collier L, Tamagnan G, Papin C, Alagille D. Effect of Leaving Group Substituents on the Microfluidic Synthesis of [18F]3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([18F]FPEB). Heterocycles 2017, 95: 807. DOI: 10.3987/com-16-s(s)49.Peer-Reviewed Original Research
2016
P4‐351: Evaluation of TAU Burden in a Cross‐Sectional Cohort of Alzheimer’S Disease Subjects Using [18F]GTP1 (GENENTECH TAU PROBE 1)
Bohorquez S, Barret O, Tamagnan G, Alagille D, Marik J, Ayalon G, Bengtsson T, de Crespigny A, Jennings D, Seibyl J, Marek K, Weimer R, Kerchner G. P4‐351: Evaluation of TAU Burden in a Cross‐Sectional Cohort of Alzheimer’S Disease Subjects Using [18F]GTP1 (GENENTECH TAU PROBE 1). Alzheimer's & Dementia 2016, 12: p1172-p1172. DOI: 10.1016/j.jalz.2016.07.096.Peer-Reviewed Original Research
2015
Imaging Studies with A2A Receptor Antagonists
Tavares A, Barret O, Seibyl J, Tamagnan G. Imaging Studies with A2A Receptor Antagonists. Current Topics In Neurotoxicity 2015, 10: 207-232. DOI: 10.1007/978-3-319-20273-0_11.Peer-Reviewed Original ResearchPositron emission tomographyValue of PETA2A receptor antagonistsSingle photon emissionPathophysiological progressionReceptor antagonistClinical studiesDifferential diagnosisParkinson's diseaseIodine-123Imaging studiesEmission tomographyNeuropsychiatric disordersSPECT probeSPECT techniqueSPECT radiotracerPET imagingA2AVivo characteristicsBrainSPECTPhoton emissionVivo propertiesRadiotracerRecent reportsO4‐07‐06: Approaches to quantitative analysis of the PET tau radiotracer [18F]AV1451
Seibyl J, Barret O, Alagille D, Jennings D, Russell D, Marek K, Tamagnan G. O4‐07‐06: Approaches to quantitative analysis of the PET tau radiotracer [18F]AV1451. Alzheimer's & Dementia 2015, 11: p285-p285. DOI: 10.1016/j.jalz.2015.07.386.Peer-Reviewed Original ResearchSynthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB)
Liang S, Yokell D, Jackson R, Rice P, Livni E, Alagille D, Tamagnan G, Collier T, Vasdev N. Synthesis of 3‐[18F]Fluoro‐5‐(2‐Pyridinylethynyl)Benzonitrile ([18F]FPEB). 2015, 41-51. DOI: 10.1002/9781118834114.ch5.Peer-Reviewed Original ResearchMetabotropic glutamate receptor subtype 5Regional brain concentrationsHealthy human subjectsBrain concentrationsBrain penetranceMGluR5 antagonistSubtype 5Parkinson's diseasePathologic processesAlzheimer's diseaseNeuropsychiatric disordersNeurodegenerative diseasesDiseaseHigh potencyHuman subjectsEvidence pointsFragile X syndromeControl testsRadiochemical purityCritical roleX syndromeMGluR5SyndromeAntagonistAbnormalitiesMonitoring loss of striatal phosphodiesterase 10A (PDE10A) with [ 18 F]MNI-659 and PET: A biomarker of early Huntington disease (HD) progression. (I11-4A)
Russell D, Jennings D, Barret O, Tamagnan G, Carroll V, Alagille D, Morley T, Papin C, Seibyl J, Marek K. Monitoring loss of striatal phosphodiesterase 10A (PDE10A) with [ 18 F]MNI-659 and PET: A biomarker of early Huntington disease (HD) progression. (I11-4A). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.i11-4a.Peer-Reviewed Original ResearchMonitoring loss of striatal phosphodiesterase 10A (PDE10A) with [ 18 F]MNI-659 and PET: A biomarker of early Huntington disease (HD) progression. (S15.004)
Russell D, Jennings D, Barret O, Tamagnan G, Carroll V, Alagille D, Morley T, Papin C, Seibyl J, Marek K. Monitoring loss of striatal phosphodiesterase 10A (PDE10A) with [ 18 F]MNI-659 and PET: A biomarker of early Huntington disease (HD) progression. (S15.004). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.s15.004.Peer-Reviewed Original Research
2014
P4‐301: PRECLINICAL AND CLINICAL PROPERTIES OF [123I]ABC577: A NOVEL RADIOIODINATED SPECT AGENT FOR IMAGING B‐AMYLOID IN THE BRAIN
Maya Y, Okumura Y, Onishi T, Shoyama Y, Barret O, Alagille D, Jennings D, Marek K, Seibyl J, Tamagnan G, Tanaka A, Shirakami Y. P4‐301: PRECLINICAL AND CLINICAL PROPERTIES OF [123I]ABC577: A NOVEL RADIOIODINATED SPECT AGENT FOR IMAGING B‐AMYLOID IN THE BRAIN. Alzheimer's & Dementia 2014, 10: p895-p895. DOI: 10.1016/j.jalz.2014.07.072.Peer-Reviewed Original Research